이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

절제 가능한 NSCLC의 Neoadjuvant Nivolumab + Ipilimumab (Galaxy 3) (GALAXY 3)

2026년 11월 5일 업데이트: Shuben Li, The First Affiliated Hospital of Guangzhou Medical University

절제 가능한 비소 세포 폐암의 Neoadjuvant Nivolumab + Ipilimumab

Neoadjuvant immunotherapy followed by surgery has emerged as the standard treatment for locally advanced and resectable non-small cell lung cancer (NSCLC). However, conventional chemotherapy components may increase treatment-related toxicity, particularly in elderly populations. Additionally, the efficacy of preoperative immunochemotherapy for patients with PD-L1 expression <1% remains to be improved. Emerging evidence has demonstrated that the combination of nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) provides superior responses in the treatment of advanced NSCLC. However, the safety and efficacy of this strategy in the neoadjuvant setting remain controversial. Therefore, this single-arm clinical trial aims to evaluate the safety and feasibility of neoadjuvant nivolumab plus ipilimumab followed by surgery in treating locally advanced and resectable NSCLC.

연구 개요

상태

모병

상세 설명

Lung cancer remains the leading cause of cancer-related death globally. Neoadjuvant immunotherapy followed by surgery has been emerged as the standard treatment for locally advanced and resectable non-small cell lung cancer (NSCLC). Numerous clinical trials highlighted the efficacy of preoperative immunochemotherapy, including remarkably shrinking the primary lesion, eliminating micrometastases and ultimately contributing to survival outcomes. Notably, studies also demonstrated neoadjuvant immunochemotherapy increased the access of modified surgery and enhanced survival prognosis of patients with locally advanced NSCLC (IIIB).

Despite these advances, certain limitations remain. Conventional chemotherapy components may elevate treatment-related toxicity, particularly in elderly populations. Additionally, the efficacy of preoperative immunochemotherapy for patients with PD-L1<1% remained to be improve. Emerging evidences demonstrated that nivolumab (anti-PD-1) combine with ipilimumab (antiCTLA-4) provided superior response for the treatment of advanced NSCLC patients. However, the safety and efficacy of this strategy in the neoadjuvant setting remain controversial. Therefore, this single-arm clinical trial aims to evaluate the safety and feasibility of neoadjuvant nivolumab plus ipilimumab followed by surgery in treating locally advanced and resectable NSCLC. The study will enroll 69 eligible participants, with the primary endpoint being pathological complete response (pCR) rate following neoadjuvant therapy.

연구 유형

중재적

등록 (추정된)

69

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

      • Guangzhou, 중국, 510120
        • 모병
        • First Affiliated Hospital of Guangzhou Medical University
        • 연락하다:
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. Informed consent must be signed.
  2. At least 18 years of age.
  3. Histologically or cytologically confirmed non-small cell lung cancer (without EGFR, ALK mutation).
  4. Have measurable and clinical stage II-IIIA with no known PD-L1 expression or PD-L1 ≤ 1%.
  5. disease eligible for surgery.
  6. No previous systematic therapy or radiotherapy.
  7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  8. At least one measurable lesion.
  9. No major organ dysfunction, including liver, kidney, and cardiac function.

Exclusion Criteria:

  1. Patients with active autoimmune disease or history of autoimmune disease.
  2. Patients have received other treatment for non-small cell lung cancer or for any other malignancy.
  3. History of allergy to study drug components.
  4. Pregnant or breast-feeding.
  5. Any mental or psychological condition that would prevent the patient from completing the study or understanding the patient information.
  6. Patients who have other malignancies.
  7. History of major surgery or serious injury within the past 3 months.
  8. HIV, HBV, HCV infection or active pulmonary tuberculosis.
  9. Vaccination within 4 weeks prior to the start of the study.
  10. Presence of underlying medical conditions that, in the investigator's judgment, could increase the risk associated with study drug administration or interfere with the assessment of toxicity and adverse events.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Neoadjuvant treatment

Patients with IIA-IIIB NSCLC will received 2-3 cycles of neoadjuvant Nivolumab (3 mg/kg intravenously (i.v.), every 3 week) plus Ipilimumab (1 mg/kg i.v., every 6 week).

Surgery will be performed within 4 to 6 weeks after completion of preoperative therapy.

After the second cycles treatment, contrast-enhanced chest CT will be performed to evaluate the tumor.

This study evaluates the safety and efficacy of neoadjuvant nivolumab plus ipilimumab for IIA-IIIB NSCLC. Based on preliminary trial results, this study proposes a new treatment regimen.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Pathological Complete Response (PCR)
기간: Within 2 weeks after surgery

Pathological complete response is predefined as no residual viable tumor cells in primary tumor and lymph nodes.

Within 2 weeks after surgery

2차 결과 측정

결과 측정
측정값 설명
기간
3-year Event-Free Survival (3-year EFS)
기간: From neoadjuvant treatment to the date of death, recurrence, progression, or the last follow-up (assessed up to 3 years).

The starting point for EFS was the initiation of neoadjuvant treatment. The endpoint for EFS was defined as the date of death, recurrence, progression, or the last follow-up.

From neoadjuvant treatment to the date of death, recurrence, progression, or the last follow-up (assessed up to 3 years).
Major Pathological Response (MPR)
기간: Within 2 weeks after surgery

Major pathological response defined as less than 10% of viable tumor cells in primary tumor.

Within 2 weeks after surgery
Safety (Rate of grade 3 and higher grade treatment-related adverse events (TRAEs))
기간: Between the last dose of neoadjuvant treatment and surgery (assessed up to 30 days)

Adverse events will be evaluated and recorded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 5.0).

Between the last dose of neoadjuvant treatment and surgery (assessed up to 30 days)
Radiological Response
기간: Between the last dose of neoadjuvant treatment and surgery

Radiographic response will be evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.

Between the last dose of neoadjuvant treatment and surgery
Postoperative complications
기간: After the surgery assess to 90 days

Postoperative complications will be evaluated and recorded after the surgery following Clavien-Dindo grade. The minimum and maximum values were grade I-V, and the higher scores mean a worse outcomes.

After the surgery assess to 90 days
Intraoperative bleeding
기간: Up to approximately 20 weeks

Intraoperative bleeding was assessed and recorded by the surgical team. Blood loss was estimated by measuring suction canister volume and weighing surgical sponges, subtracting irrigation fluid.

Up to approximately 20 weeks
The Quality of Life
기간: From the Day 1 to at least 90 days after surgery

The quality of life will be evaluated and recorded according to the EORTC QLQ-C30. The minimum and maximum values were 0-100, and the higher scores mean a better outcome.

From the Day 1 to at least 90 days after surgery
Duration of surgery
기간: Up to approximately 20 weeks

Duration of surgery is the time spent in surgery.

Up to approximately 20 weeks
Hospital Stay
기간: Up to approximately 20 weeks

Hospital Stay is the length of inpatient time spent in hospital.

Up to approximately 20 weeks
Feasibility (Completion rate of neoadjuvant treatment and surgery)
기간: From date of treatment allocation until surgery, assessed up to 5 months

Propotion of patients who complete neoadjuvant treatment and receive surgery within 42 days after neoadjuvant treatment

From date of treatment allocation until surgery, assessed up to 5 months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2025년 6월 19일

기본 완료 (추정된)

2030년 3월 31일

연구 완료 (추정된)

2030년 10월 31일

연구 등록 날짜

최초 제출

2025년 3월 30일

QC 기준을 충족하는 최초 제출

2025년 4월 11일

처음 게시됨 (실제)

2025년 4월 15일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 9일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 5일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

미국에서 제조되어 미국에서 수출되는 제품

예

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다